喷布洛尔双盲试验：一种治疗心绞痛的新型β受体阻滞剂。
A double-blind trial of penbutolol: a new beta-receptor blocking agent in the treatment of angina pectoris.
作者信息
Agarwal A K, Ahuja R C, Chandra M, Gupta N N, Hasan M
出版信息
J Int Med Res. 1976;4(6):410-7. doi: 10.1177/030006057600400606.
A double-blind placebo controlled study of angina pectoris with penbutolol was undertaken in parallel groups in fifty-two patients. The duration of the study was six weeks. The dosage range for penbutolol was 8 mg to 50 mg per day. Six patients were dropped from the analysis. Seventeen patients (81%) in the penbutolol series exhibited a 50% reduction in anginal attacks, NTG consumption and subjective improvement. Significant reduction in nitrite intake was observed. Effort tolerance was improved significantly in those receiving penbutolol. Penbutolol was well-tolerated.
采用双盲安慰剂对照研究，将52例心绞痛患者分为平行组，使用喷布洛尔进行治疗。研究持续时间为6周。喷布洛尔的剂量范围为每日8毫克至50毫克。6例患者被排除在分析之外。喷布洛尔组有17例患者（81%）心绞痛发作次数、硝酸甘油消耗量减少50%，主观症状改善。亚硝酸摄入量显著减少。接受喷布洛尔治疗的患者运动耐量显著提高。喷布洛尔耐受性良好。
Zotero 插件